Seeking Alpha

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

-- Long-term durability observed for CB-010 allogeneic cell therapy at dose level 1 in ANTLER trial for r/r B-NHL -- -- ANTLER trial enrolling patients at dose level 3 -- 6 of 6 patients achieved a ...
Seeking Alpha

Caribou Biosciences: Antlers Up, Bullish Run In Phase 1 Trials

Caribou Biosciences shows promise with a 94% overall response rate in Phase 1 trials for CB-010, but faces a competitive CAR-T landscape. Financially robust with $292.5M liquid assets, but concerns ...
Business Insider

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts ...
WKRG

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, ...
WNCT

Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients

BERKELEY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced initiation of ...